DadFinStart your free week
DadFin › Stocks › Healthcare › IMCR

Immunocore Holdings plc (IMCR) stock score

Healthcare · Biotechnology · United Kingdom

$29.39 ▲ +1.03% today

19.7
Dad Score, out of 100
weak

Immunocore Holdings plc (IMCR) is a Biotechnology company in the Healthcare sector, listed in the United Kingdom. On DadFin's weekly run it scores 19.7 out of 100 on the Dad Score, a weak reading that places the business ahead of 20% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #755 of 974. Its strongest axes are quality, growth and conviction; its weakest are valuation and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Weak
Quality
Above average
Growth
Above average
Price action
Below average
Risk
Average
Conviction
Above average
Liquidity
Average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)-39.4×
Dividend yield0.00%
Return on capital-0.9%
Operating margin-2.6%
Revenue growth (YoY)+29.0%
FCF yield-1.0%
Net debt / EBITDA-588.96×
Piotroski F-Score4 / 9
52-week change-12.6%
Market cap$1.5B
Next earnings—

What subscribers see on IMCR

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate51.2middling$127.8B
MRNAModerna, Inc.23.4weak$75.9B
REGNRegeneron Pharmaceuticals, Inc.91.1strong$75.7B
ARGXargenx SE55.1middling$57.5B
RVMDRevolution Medicines, Inc.40.6middling$44.3B
ONCBeOne Medicines AG94.5strong$40.7B
RPRXRoyalty Pharma plc70.8good$33.0B
ALNYAlnylam Pharmaceuticals, Inc.83.8good$29.4B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.